CORCEPT THERAPEUTICS INC
CORT · Healthcare · $10.1B mkt cap · FY2025 filings · · not refreshed in 36 days · Wide moat ·
On the watchlist
The five investor questions
2021–2025 (latest 5 aligned FYs; v3 window cap 5): revenue $366M to $761M, increasing; diluted EPS 0.89 to 0.82, decreasing.
Median gross margin 98.3% over 10y, very stable.
Median ROIC 25.6%, above the 12% hurdle in 90% of years.
Net cash position — no leverage risk.
Owner earnings changed +32.2%/yr over up to the ten most recent annual observations.
Price vs. value if growth stopped today
A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.
- $107M
- $11.22
- $11.22
- $95.36
- 750% above value if growth stopped today
What today’s price assumes: owner earnings growing ~53%/yr over 5 years. The zero-growth estimate assumes owner earnings stay flat (0% growth).
How to read this
We solve for the constant annual change in owner earnings that would make the five-year zero-growth estimate equal today’s price. This keeps the existing model inputs and calculation unchanged; it is an expectations lens, not a forecast.
This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. Flag status unavailable — four adjacent recent FY revenue observations are required.
Among the current top-score group, the median current price is 239% above the zero-growth estimate across 48 of the current top 50 companies by Moat Score with both values.
Score records captured Jul 26, 2026.
Exactly which 50 companies?
FTNT, META, MEDP, IBEX, MSFT, GOOGL, LULU, ANF, IDXX, TXRH, FHI, QLYS, FFIV, ADBE, LLY, MANH, VEEV, GRMN, SSD, MNST, DOCS, MCO, CPRT, NTAP, LRCX, NVDA, CORT, SFM, MPTI, ULTA, SN, RMD, ROL, PAYC, IRMD, INTU, DECK, MORN, LGCY, DAL, GWW, ISRG, MPWR, CTAS, LOPE, MRK, CMG, FAST, BKNG, ORLY
Missing a usable price or zero-growth estimate: ANF, BKNG.
Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.
Fundamentals
We couldn't reach the fundamentals service just now, so we won't show a stale or guessed series for CORT. Try again shortly.
Visual explainers
The filing-backed explainer service is temporarily unavailable, so no partial or guessed chart is shown.
Moat Score history
Breaks in the line mark methodology or normalizer upgrades — readings across versions aren’t compared, so a level shift there isn’t a change in the business.
Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars
- Normalizer upgraded unstamped (version unknown)tomoat-xbrl-normalizer@1.1.0 — readings across versions aren’t comparedJul 26, 2026
- Methodology upgraded moat-index@2.0.0tomoat-index@3.0.0 — readings across versions aren’t comparedJul 23, 2026
- Methodology upgraded moat-index@1.2.0tomoat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026
Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.
Insider activity
Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”
These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.
The insider-filing service is temporarily unavailable, so no partial or guessed answer is shown for CORT.
Healthcare context
#4 of 710 scored Healthcare companies, ranked by Moat Score.
Nearest peers by Moat Score
- #2LLY ELI LILLY & Co94.3 out of 100, Wide moatWide moat
- #3GRMN GARMIN LTD93.8 out of 100, Wide moatWide moat
- #5RMD ResMed Inc.91.6 out of 100, Wide moatWide moat
- #6IRMD IRADIMED CORPORATION90.6 out of 100, Wide moatWide moat
Compare CORT with its nearest peers →All Healthcare companies on the Index →
Common questions about CORT
- Does CORCEPT THERAPEUTICS INC have an economic moat?
- Based on its FY2025 SEC filings, the Moat Index scores CORCEPT THERAPEUTICS INC (CORT) 91.9 out of 100 — a Wide moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 71, pricing power 100, returns on capital 97, balance-sheet safety 100, capital allocation 92.
- Is CORT trading below the conservative owner-earnings estimate?
- The value if growth stopped today — a zero-growth baseline — is $11.22 per share. It capitalizes normalized owner earnings at a 9% rate and assumes 0% growth. Versus a recent price of $95.36, that is 750% above value if growth stopped today. The model also publishes a capped-growth comparison, but the zero-growth estimate is the cautious baseline. It assumes trailing owner earnings persist and is unreliable for declining businesses. This is an educational estimate from primary SEC filings, not intrinsic value as a fact or investment advice.
- How has CORT's Moat Score changed over time?
- The record logs 16 readings since Jul 17, 2026; the latest reads 91.9 out of 100 (wide moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.